Norway: A premier destination for clinical trials
Page date: published 14 March 2025; updated 17 September 2026; 6 min read (as rendered).
The article describes NorTrials as a national entry point created through Norway’s 2021 clinical-trials action plan. It says six centres at university hospitals cover brain health, cancer, cardiovascular disease, clinical immunology, gastrointestinal disease and medical devices. The page lists health registries, biobanks, specialist clinicians, molecular diagnostics and a publicly funded hospital system as assets for clinical research, and frames NorTrials as a way to coordinate public hospitals, contract research organisations and industry.
The radiopharmaceutical section describes Norway’s experience with early-phase and later-stage studies and cites Oslo University Hospital facilities for production and trials. It names Xofigo, developed by Algeta and marketed by Bayer, as a Norwegian radiopharmaceutical example. On cancer trials, the article references the 2025–2035 cancer strategy’s aim to double cancer-patient participation, estimating that this would represent around 15% of cancer patients. It also describes theranostics and Eli Lilly’s SUNRAY-01 study of a drug for advanced non-small-cell lung cancer with a KRAS G12C mutation.
These descriptions, strategic goals and company/study status are attributed to the article and may change. This is informational material, not medical guidance.
Related link: Health and life science.